Sucampo Pharmaceuticals - M&A Summary, Ownership, and Business Overview

Life ScienceCompany

Sucampo Pharmaceuticals M&A Summary

Sucampo Pharmaceuticals has acquired 2 companies of its own. A total of 1 acquisition came from private equity firms.

Sucampo Pharmaceuticals’ largest acquisition to date was in 2015, when it acquired R-Tech Ueno for $275M. Sucampo Pharmaceuticals has acquired in 1 US state, and 2 countries. The Company’s most targeted sectors include life science (100%).

Sucampo Pharmaceuticals Ownership

Who owns Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals is owned by Mallinckrodt. It was acquired on December 26, 2017.

Sucampo Pharmaceuticals Business Overview

Where is Sucampo Pharmaceuticals headquartered?

Sucampo Pharmaceuticals is headquartered in Bethesda, Maryland.

What is Sucampo Pharmaceuticals’ revenue?

Sucampo Pharmaceuticals disclosed revenue of 115M USD for 2014 and 89M USD for 2013.

How many employees does Sucampo Pharmaceuticals have?

Sucampo Pharmaceuticals has 80 employees.

What sector is Sucampo Pharmaceuticals in?

Sucampo Pharmaceuticals is a life science company.

When was Sucampo Pharmaceuticals founded?

Sucampo Pharmaceuticals was founded in 1996.

M&A Summary

  • M&A Total Activity2
    • M&A Buy Activity2
  • Total Sectors Invested 1
  • Total Countries Invested 2
  • M&A Buy/Sell Connections 1
  • M&A Advisors 4

Sucampo Pharmaceuticals, Inc.

4520 East West Highway, 3rd Floor,
Bethesda, Maryland 20814
United States,
(301) 961-3400
www.sucampo.com

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of highly specialized medicines. Sucampo has a late-stage pipeline of product candidates in clinical development for orphan disease areas, including VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C, a rare progressive genetic disorder. VTS-270 has also been granted breakthrough therapy designation in the U.S. Sucampo has an exclusive option for the North American rights to CPP-1X/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. The company has two marketed products – AMITIZA and RESCULA.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.0/yr) # 2 - - - - - 2
vol $475M $475M
Sell (0.0/yr) # - - - - - - 0
  2

Most Recent M&A

Company Date Value Type
Vtesse, Inc. 2017-04-03 200M USD Add-on Acquisition
Gaithersburg, Maryland · www.vtessepharma.com
R-Tech Ueno Ltd. 2015-12-07 275M USD Add-on Acquisition
Tokyo, Japan · www.rtechueno.com
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 2 (100%) 475M (100%) - -
Total 2 $475M - -

By Geo

State/Country Buy Value Sell Value
Japan 1 275M - -
United States 1 200M - -
  Maryland 1 200M - -
Domestic 1 (50%) 200M (42%) - -
Cross-border 1 (50%) 275M (58%) - -
Total 2 $475M - -

Top M&A Advisors

Financial Deals
Jefferies
 1
Moelis & Co.
 1
Legal Deals
Cooley
 2
Mori Hamada & Matsumoto
 1

Deal Values

buy # Total
$100M to $1B 2 $475M
TOTAL $475M
Largest R-Tech Ueno Ltd.
$275M (2015-12-07)

M&A Connections

Deals
Acquired from
Investor(s)
50%
1 (50%)

Company Summary

SECTOR

Life Science

Revenue

115   30% 2014
89   10% 2013
81   2012
(millions of USD)

Employees

80

Established

1996

 Subscribe to unlock this and 209,235
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 202K M&A Transactions
  • 205K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for Sucampo Pharmaceuticals

Maryland Companies , Life Science Companies , United States Companies , Maryland Life Science Companies , Maryland Life Science with Acquisitions , Maryland Life Science with Divestitures

Related Lists for Maryland Companies

Largest Maryland Companies , Acquisitive Maryland Companies , Recently Acquired Maryland Companies , Recently Sold Maryland Companies , Private Maryland Companies , Public Maryland Companies , Acquired Maryland Companies , PE Backed Maryland Companies

Related Lists for Life Science Companies

Largest Life Science Companies , Acquisitive Life Science Companies , Recently Acquired Life Science Companies , Recently Sold Life Science Companies , Private Life Science Companies , Public Life Science Companies , Acquired Life Science Companies , PE Backed Life Science Companies

Related Lists for United States Companies

Largest United States Companies , Acquisitive United States Companies , Recently Acquired United States Companies , Recently Sold United States Companies , Private United States Companies , Public United States Companies , Acquired United States Companies , PE Backed United States Companies
Mergr

Product

Company

Legal